Lonafarnib

What Is Lonafarnib?[edit | edit source]

Lonafarnib (ZOKINVY) is a prescription medicine used to:

lower the risk of death in adults and children 12 months of age or older with Hutchinson-Gilford Progeria Syndrome (HGPS), who have a certain body surface area.
treat adults and children 12 months of age or older with certain types of Progeroid Laminopathies, who have a certain body surface area.

This medicine is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

For the treatment of processing-deficient Progeroid Laminopathies with either:

Lonafarnib inhibits farnesyl transferase to prevent farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.

Do not take ZOKINVY if you are taking:

Start at 115 mg/m2 twice daily with morning and evening meals
After 4 months, increase to 150 mg/m2 twice daily
Round all total daily doses to nearest 25 mg increment
Swallow capsules whole
If unable to swallow capsules, mix contents with Ora Blend SF®, Ora-Plus®, orange juice, or applesauce

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

Common possible side effects of this medicine include:

ZOKINVY may cause serious side effects, including:

Advise females of reproductive potential of the risk to a fetus and to use effective contraception.
Monitor for changes in electrolytes, complete blood counts, and liver enzymes.
Monitor renal function at regular intervals
Perform ophthalmological evaluation at regular intervals and at the onset of any new visual changes.
Advise females and males of reproductive potential about Impaired Fertility.

There are no human data on ZOKINVY use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Advise pregnant women of the risk to a fetus.

The safety and effectiveness of ZOKINVY for the treatment of HGPS and processing-deficient Progeroid Laminopathies (with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations) have been established in pediatric patients 12 months of age and older.
The safety and effectiveness of ZOKINVY in pediatric patients less than 12 months of age have not been established.

Lonafarnib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.